Last updated 4 days ago

A Study to Investigate the Efficacy and Safety of Dato-DXd-based Combinations in Participants With TROP2 NMR+ NSCLC

250 patients around the world
Available in Argentina, Brazil, United States
This is a Phase II, open-label, multicentre, multi-cohort platform study to determine the efficacy and safety of Datopotamab Deruxtecan (Dato-DXd)-based combinations for the treatment of TROP2 NMR+ NSCLC. This study is designed as non-comparative. Participants will be randomised to Treatment A or B. In the module 1 of this study, Dato-DXd-based regimens will be assessed in participants with non-AGA NSCLC whose tumours have been prospectively identified as TROP2 NMR+. The proposed primary objectives are to assess the efficacy of Dato-DXd combined with durvalumab and carboplatin and Dato-DXd combined with durvalumab in terms of PFS per RECIST 1.1 as assessed by the investigator. Participants in both treatment groups will receive study treatment medicines until investigator-assessed radiological progression per RECIST 1.1, unacceptable toxicity, withdrawal of consent, or an intervention discontinuation criterion is met. There is no maximum limit to the number of cycles of Dato-DXd and/or durvalumab that a participant in either treatment group can receive. The maximum treatment for carboplatin is 4 cycles. The study will be conducted in several countries worldwide.
AstraZeneca
250Patients around the world

This study is for people with

Lung cancer
Non-small cell lung carcinoma

Requirements for the patient

From 18 Years
All Gender

Medical requirements

Participant must be ≥ 18 years of age at the time of signing the ICF.
Pathologically documented NSCLC that.
Has documented non-squamous histology.
Is TROP2 NMR positive.
Documented lack of sensitising EGFR mutation, as well as ALK and ROS1 rearrangements on tumour tissue.
Stage IIIB or IIIC disease not amenable to surgical resection or definitive chemoradiation, or Stage IV metastatic NSCLC at the time of randomisation, as per the American Joint Committee on Cancer Staging System, 9th Edition.
The ECOG PS of 0 to 2.
Known tumour PD-L1 status.
Minimum life expectancy of 12 weeks.
Provision of acceptable FFPE tumour sample from a lesion not previously irradiated.
At least 1 lesion, not previously irradiated, that qualifies as a RECIST 1.1 target lesion at baseline.
Adequate bone marrow reserve and organ function.
Contraceptive use by participants or participant partners.
Capable of giving signed informed consent.
Provision of signed and dated optional informed consent.
As judged by the investigator, any evidence of diseases, chronic diverticulitis or previous complicated diverticulitis, or history of allogenic organ transplant, which, in the investigator's opinion, makes it undesirable for the participant to participate in the study or that would jeopardise compliance with the protocol.
History of another primary malignancy except for malignancy treated with curative intent with no known active disease within 3 years before the first dose of study intervention and of low potential risk for recurrence, adequately resected basal cell carcinoma of the skin or squamous cell carcinoma of the skin, lentigo maligna that has undergone potentially curative therapy, or adequately treated in situ disease without evidence of disease.
Squamous histology or mixed SCLC and NSCLC, or sarcomatoid variant of NSCLC, or lung neuroendocrine tumours.
Has documented tumour genomic alterations in EGFR, ALK, ROS1, NTRK, BRAF V600E, RET, MET exon 14, or any other actionable driver oncogenes for which there are locally approved and available targeted first-line therapies.
Note: Participants whose tumours harbour KRAS mutations are eligible for the study.
Persistent toxicities caused by previous anti-cancer therapy, excluding alopecia or vitiligo, not yet improved to Grade ≤ 1 or baseline.
Active or prior documented autoimmune, connective tissue or inflammatory disorders, autoimmune pneumonitis, or autoimmune myocarditis.
Spinal cord compression or CNS metastases, unless asymptomatic, stable, and not requiring treatment with corticosteroids or anticonvulsants for at least 7 days prior to randomisation.
History of leptomeningeal carcinomatosis or metastasis.
Clinically significant corneal disease.
Has active or uncontrolled HBV or HCV infection.
Known HIV infection that is not well controlled.
Uncontrolled infection requiring systemic antibiotics, antivirals, or antifungals, suspected infections or inability to rule out infections.
Known to have active tuberculosis infection.
Mean resting QTcF > 470 ms, regardless of gender, obtained from triplicate 12-lead ECGs performed at screening.
Uncontrolled or significant cardiac disease.
History of ILD/pneumonitis.
Has clinically severe pulmonary function compromised.
Prior exposure to.
Any agent, including ADC, containing a chemotherapeutic agent targeting topoisomerase I.
Chemotherapy or any other systemic therapy for first-line Stage IIIB, IIIC, or IV NSCLC.
TROP2-targeted therapy.
Chloroquine/hydroxychloroquine without an adequate treatment washout period.
Participants who have received any prior adjuvant, neoadjuvant, or definitive chemoradiation for early stage disease (Stage I to III) are eligible, provided they meet the protocol-defined conditions.
Current or prior use of immunosuppressive medication within 14 days before the first dose of study intervention.
Any concurrent anti-cancer treatment.
Any concomitant medication known to be associated with Torsades de Pointes.
Receipt of live, attenuated vaccine within 30 days prior to the first dose of study intervention.
Received prior radiotherapy to the brain within 2 weeks of start of study intervention or received palliative radiotherapy to the chest within 4 weeks of start of study intervention or has ongoing radiation-related toxicities requiring corticosteroids.
Major surgical procedure or significant traumatic injury within ≤ 4 weeks of the first dose of study intervention or an anticipated need for major surgery during the study.
Participation in another clinical study with a study intervention or investigational medicinal device administered in the last 4 weeks prior to randomisation or concurrent participation in another clinical study.
Participants with a known history of severe hypersensitivity reactions to study intervention or any excipients of these products.
Participants with a known history of severe hypersensitivity reactions to other monoclonal antibodies.
Allocation to a stratum that has reached the cap.
Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).
Judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements.
For females only: Is pregnant (confirmed with positive serum pregnancy test), or breastfeeding, or planning to become pregnant.
LinkedinInstagramFacebook
Terms and ConditionsPrivacy Policy